WEREWOLF THERAPEUTICS, INC. Operating Cash Flow
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Operating Cash Flow of -$3.97 million for the 6-month period ending 2026-06-30, per its S-4 filed 2026-09-22.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $6.63M.
- WEREWOLF THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$10.60M.
- WEREWOLF THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$11.02M.
- WEREWOLF THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$15.16M.
- WEREWOLF THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$32.61M.
- WEREWOLF THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$40.60M.
- WEREWOLF THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2021 was -$42.88M.
- WEREWOLF THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2020 was -$18.62M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.63M derived: S-4 6 month − 10-Q 3 month · filed 2026-09-22 | -$3.97M S-4 · filed 2026-09-22 | -$14.99M derived: sum of 3 quarters · filed 2026-09-22 | -$30.15M derived: sum of 4 quarters · filed 2026-09-22 |
| 2026-03-31 | -$10.60M 10-Q · filed 2026-05-07 | -$21.62M derived: sum of 2 quarters · filed 2026-09-22 | -$36.78M derived: sum of 3 quarters · filed 2026-09-22 | -$51.94M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-12-31 | -$11.02M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | -$26.18M derived: sum of 2 quarters · filed 2026-09-22 | -$41.34M derived: sum of 3 quarters · filed 2026-09-22 | -$60.29M S-4 · filed 2026-09-22 |
| 2025-09-30 | -$15.16M derived: 10-Q 9 month − S-4 6 month · filed 2025-11-04 | -$30.32M derived: sum of 2 quarters · filed 2026-09-22 | -$49.27M 10-Q · filed 2025-11-04 | -$63.52M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-06-30 | -$15.16M derived: S-4 6 month − 10-Q 3 month · filed 2026-09-22 | -$34.11M S-4 · filed 2026-09-22 | -$48.36M derived: sum of 3 quarters · filed 2026-09-22 | -$60.83M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-03-31 | -$18.95M 10-Q · filed 2026-05-07 | -$33.20M derived: sum of 2 quarters · filed 2026-09-22 | -$45.66M derived: sum of 3 quarters · filed 2026-09-22 | -$59.84M derived: sum of 4 quarters · filed 2026-09-22 |
| 2024-12-31 | -$14.25M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | -$26.71M derived: sum of 2 quarters · filed 2026-09-22 | -$40.89M derived: sum of 3 quarters · filed 2026-09-22 | -$56.19M S-4 · filed 2026-09-22 |
| 2024-09-30 | -$12.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$26.64M derived: sum of 2 quarters · filed 2025-11-04 | -$41.94M 10-Q · filed 2025-11-04 | -$46.52M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | -$14.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$29.47M 10-Q · filed 2025-08-14 | -$34.06M derived: sum of 3 quarters · filed 2025-08-14 | -$41.27M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$15.30M 10-Q · filed 2025-05-08 | -$19.88M derived: sum of 2 quarters · filed 2025-05-08 | -$27.09M derived: sum of 3 quarters · filed 2025-05-08 | -$38.01M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$4.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$11.79M derived: sum of 2 quarters · filed 2025-03-11 | -$22.71M derived: sum of 3 quarters · filed 2025-03-11 | -$32.61M 10-K · filed 2025-03-11 |
| 2023-09-30 | -$7.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$18.13M derived: sum of 2 quarters · filed 2024-11-07 | -$28.03M 10-Q · filed 2024-11-07 | -$39.90M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$10.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$20.82M 10-Q · filed 2024-08-08 | -$32.69M derived: sum of 3 quarters · filed 2024-08-08 | -$47.16M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$9.90M 10-Q · filed 2024-05-03 | -$21.77M derived: sum of 2 quarters · filed 2024-05-03 | -$36.24M derived: sum of 3 quarters · filed 2024-05-03 | -$36.54M derived: sum of 4 quarters · filed 2024-05-03 |
| 2022-12-31 | -$11.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$26.34M derived: sum of 2 quarters · filed 2024-03-07 | -$26.64M derived: sum of 3 quarters · filed 2024-03-07 | -$40.60M 10-K · filed 2024-03-07 |
| 2022-09-30 | -$14.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$14.78M derived: sum of 2 quarters · filed 2023-11-14 | -$28.73M 10-Q · filed 2023-11-14 | -$41.40M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$303.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$14.25M 10-Q · filed 2023-08-10 | -$26.93M derived: sum of 3 quarters · filed 2023-08-10 | -$39.34M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$13.95M 10-Q · filed 2023-05-11 | -$26.62M derived: sum of 2 quarters · filed 2023-05-11 | -$39.04M derived: sum of 3 quarters · filed 2023-05-11 | -$49.50M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$12.67M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$25.09M derived: sum of 2 quarters · filed 2023-03-23 | -$35.55M derived: sum of 3 quarters · filed 2023-03-23 | -$42.88M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$12.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$22.88M derived: sum of 2 quarters · filed 2022-11-10 | -$30.20M 10-Q · filed 2022-11-10 | -$36.21M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$10.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$17.79M 10-Q · filed 2022-08-11 | -$23.80M derived: sum of 3 quarters · filed 2022-08-11 | -$28.72M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$7.33M 10-Q · filed 2022-05-10 | -$13.34M derived: sum of 2 quarters · filed 2022-05-10 | -$18.26M derived: sum of 3 quarters · filed 2022-05-10 | -$22.55M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$6.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | -$10.93M derived: sum of 2 quarters · filed 2022-03-24 | -$15.22M derived: sum of 3 quarters · filed 2022-03-24 | -$18.62M 10-K · filed 2022-03-24 |
| 2020-09-30 | -$4.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$9.22M derived: sum of 2 quarters · filed 2021-11-10 | -$12.62M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$4.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$7.69M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$3.40M 10-Q · filed 2021-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |